New schizophrenia drug candidate begins first human safety tests
NCT ID NCT07585383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug called KR23248 in 66 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo. This study does not aim to treat any disease but to gather important safety information for future research on schizophrenia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a video call strengthen families facing schizophrenia?
- Virtual family therapy may tame schizophrenia symptoms — a trial investigates
- Could a Once-Every-Few-Weeks shot replace daily pills for schizophrenia?
- Can a tailored self-management program improve health outcomes for those with serious mental illness?
- PET scans reveal how antipsychotics target key brain receptors in schizophrenia
- Immune clues in schizophrenia: could inflammation subtypes guide treatment?